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Introduction: In the last 20 years, the rate of exposure to marijuana has increased dramatically, even in the
pediatric population. Effects of intoxication are variable, more severe neurological symptoms can be observed
following ingestion, thus hospital or intensive care unit admission is often required. Usually cannabinoids
intoxicated patients are treated with administration of benzodiazepines or opioids, accepting the related risk of
intubation and mechanical ventilation. Dexmedetomidine is a highly selective α2-adrenergic receptor agonist, with
no effect on the respiratory drive and pattern and produces a good level of sedation, allowing to avoid the
administration of other sedatives. To our knowledge, this is the first reported case of dexmedetomidine use to
support a cannabis intoxicated patient.
Case presentation: A 19-month-old Caucasian boy was presented to our emergency department. At the time of
his arrival, he was somnolent with paroxysms of agitation, breathing spontaneously and hemodynamically stable.
The results of all investigations were negative, but the result of the immunochemical screening of his urine was
positive for Δ9-tetrahydrocannabinol. The patient was admitted to the pediatric intensive care unit and treated with
a continuous infusion of dexmedetomidine.
Conclusions: Dexmedetomidine is a fairly safe and effective antidote for pediatric marijuana or natural cannabinoid
exposures. Its properties and potential to allow for “cooperative” sedation make it a more attractive choice with
fewer side effects than benzodiazepines or opioids.
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In the last 20 years, a progressively higher prevalence of
cannabis consumption has been detected. Thus, the rate
of exposure has increased dramatically, even in the
pediatric population. Historically, significant effects fol-
lowing unintentional pediatric marijuana ingestion were
rare, and the relevant literature consists of single case
reports and a small case series [1–5]. In the United
States, the decriminalization of medical marijuana has
resulted in a significant increase in marijuana exposures
in young children, and more severe symptoms can be
observed, owing to the higher concentrations of
marijuana in edible and medical products [6, 7].
Accidental consumption is mostly oral among chil-
dren, and effects are variable, with slow onset and* Correspondence: flora.cipriani@yahoo.com
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and range from lethargy to deep coma [1–3], with pe-
riods of agitation and psychotic reactions, dysphoric
screaming and posturing; seizures are rare [3]. Possible
non-neurological symptoms are bradypnea and apnea,
mydriasis, hyporeflexia and hypotonia, conjunctival
hyperemia, tremor, emesis and tachycardia.
Ingested marijuana has an absorption of 5% to 10 %
and results in effects 1 hour after consumption. Δ9-tetra-
hydrocannabinol (THC) is the primary psychoactive
component of marijuana. It reaches peak plasma con-
centrations after 1–6 hours, and its plasma levels remain
elevated, with effects lasting up to 5–24 hours.
Marijuana is metabolized in the liver, and the metabo-
lites are excreted in urine. Urinary metabolites can be
detected up to 12 days after consumption [5].
Management of acute marijuana intoxication is pri-
marily supportive. Benzodiazepines may be considered
to control panic attacks and agitation [4]. Childrenrticle distributed under the terms of the Creative Commons Attribution License
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and for 24 hours if symptomatic because THC has a ter-
minal half-life of 20–30 hours [8].
In this report, we describe a pediatric case of accidental
cannabinoid intoxication treated with dexmedetomidine
to support the patient, thereby avoiding cardiovascular in-
stability and the risk of mechanical ventilation.Table 1 Objective Pain Scale (OPS)










Movement 0: No movements 1 0
1: Restless
2: Thrashing or rigid










Specific distress behaviors associated with pain are helpful in quantifying pain
or agitation in children unable to provide self-reported information. Several
behavioral scales are available. The OPS is one of them and is commonly used
in clinical practice. This scale incorporates four pain behaviors (crying, movement,
agitation and verbalization) and blood pressure variation, a physiological measure
of pain. Each of these categories is scored from 0 to 2, with a score ≥6 indicating
intense painCase presentation
A 19-month-old Caucasian boy was presented to our
emergency department in the morning. At the time of
arrival, he was lethargic, responsive to painful stimulus
with jarring cry, and with isocoric and isocyclic midpoint
pupils. He was breathing spontaneously on room air
with peripheral saturation of oxygen (SpO2) around 96
% and periods of apnea, lasting around 5 seconds, that
were not associated with bradycardia. Hemodynamically,
he was stable (systolic blood pressure: 125mmHg; heart
rate: 160 beats per minute). The patient was somnolent
with paroxysms of agitation. The mother reported that
the somnolence had developed about 12 hours before
presentation, after the child had eaten something he had
found on the ground at a park. Emergency brain com-
puted tomography showed no vascular, bone or paren-
chymal alterations. Hematological and blood chemistry
investigations were normal. Immunochemical screening
of his urine was performed, and the results were negative
for everything (amphetamines, barbiturates, benzodiaze-
pines, cocaine, methadone, opiates and tricyclic anti-
depressants) but natural cannabinoids (THC); synthetic
cannabinoids were not tested. Subsequently, we collected
serial blood samples for quantitative testing and a hair
sample to evaluate chronic cannabis exposure.
We admitted the patient to our pediatric intensive care
unit (PICU) for monitoring and supportive treatment.
The child had normal vital signs and was resting quietly
for most of the time; however, these periods of calm
were interrupted by sudden-onset agitated outbursts of
violent behavior. First, we tried to control these phases
with non-pharmacological measures: quiet ambience in
the room, toys and colors, music and videos, presence of
parents and gentle wrapping of the child in the bed. At a
later stage, we tried to control his agitation by adminis-
tering an intravenous bolus of midazolam (1mg), which
was followed by a brief obstructive apnea episode. Con-
sidering our experience with dexmedetomidine and
knowing it has no depressive respiratory effect [9], we
started a dexmedetomidine continuous infusion, without
any bolus, at the rate of 0.4μg/kg/hr and increased the
rate progressively up to 0.7μg/kg/hr. The clinical effects
are shown in Table 1 and Fig. 1. The patient’s episode of
agitation disappeared with the dexmedetomidine con-
tinuous infusion, and he was quiet and cooperative. Hisvital sign parameters stabilized (Fig. 1), and his SpO2
stayed around 97 % to 100 % with spontaneous breath-
ing on room air. After a 24-hour infusion, we progres-
sively reduced dexmedetomidine until it was stopped
while observing the patient’s reaction. He was calm, had
a full recovery of consciousness and his vital signs were
stable. The patient was transferred to the pediatric gen-
eral ward.
Discussion
To the best of our knowledge, this is the first reported
case of a pediatric patient with cannabinoid intoxication
who was treated with dexmedetomidine. In the reported
case, the use of dexmedetomidine allowed us to control
the patient’s phases of agitation and aggressiveness with-
out administering benzodiazepines or opioids, thereby
avoiding any delirium or respiratory depression and thus
the risk of intubation, mechanical ventilation and the
need of further sedation. It was possible to evaluate the
state of consciousness of the child and to move him out
of our PICU only 24 hours after admission.
Dexmedetomidine was approved by the U.S. Food and
Drug Administration in 1999 in the United States for
use only as a short-term medication (<24 hours) for an-
algesia and sedation in the intensive care unit (ICU). Its
unique properties render it suitable for sedation and an-
algesia during the whole peri-operative period: as a pre-
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Fig. 1 Variation of heart rate (HR), systolic blood pressure (SBP) and Objective Pain Scale (OPS) score over time. The figure shows the trend of the
patient’s vital signs (HR and SBP), which decreased after the start of the dexmedetomidine (Dex) continuous infusion (at 12 P.M.) and later remained
stable. The graph also shows a zeroing of the OPS score because the child stayed quiet a few hours after the beginning of dexmedetomidine
treatment. bpm, Beats per minute
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analgesic. It is widely used in the pediatric setting for
sedation in ICU, as an analgesic after surgery, in burn
patients who are inadequately sedated with opioids or
benzodiazepines, for sedation in both non-invasive (i.e.,
infants diagnostic radiologic procedures) and invasive
(i.e., placement of central venous lines, bronchoscopy,
laryngoscopy, cardiac catheterization) procedures, in the
post-anesthesia care unit to decrease the incidence of
agitation, and to perform awake craniotomies [10].
Dexmedetomidine is an imidazole compound and a
highly selective α2-adrenergic receptor agonist. These re-
ceptors are pre- and post-synaptic. Through a negative
feedback mechanism, pre-synaptic α2-adrenergic recep-
tors inhibit the release of norepinephrine, terminating
the propagation of pain signals.
Dexmedetomidine has sedative and analgesic proper-
ties. Both supraspinal and spinal sites modulate the
transmission of nociceptive signals in the central ner-
vous system, and even peripheral α2-adrenergic recep-
tors may mediate anti-nociception. At the spinal level,
dexmedetomidine produces its analgesic effects by acting
on the α2-adrenergic receptors in the dorsal horns of the
spinal cord; thus, the drug inhibits the firing of nocicep-
tive neurons and modulates the release of substance P.
Dexmedetomidine acts even at a central level. The locus
coeruleus is an important modulator of vigilance and
nociceptive neurotransmission and has a high density of
α2-adrenergic receptors; therefore, the major sedative,
anxiolytic and even anti-nociceptive effects of dexmede-
tomidine result primarily from its activity on this site.
The sedation produced by dexmedetomidine is different
from that produced by GABAergic drugs (benzodiazepinesand propofol). Patients receiving dexmedetomidine infu-
sions have been described as being very easy to wake up
and having the ability to follow commands and cooperate;
undisturbed, patients were noted to fall asleep right away.
This is called “cooperative sedation” [11]. Moreover, the
α2-adrenergic agonists also act through the endogenous
sleep-promoting pathways to exert their sedative effect
[12]. There is no respiratory depression and limited cardio-
vascular effects, providing wide safety margins.
The half-life of dexmedetomidine is around 2 hours,
with a rapid distribution phase and a half-life of distribu-
tion of approximately 6 minutes. No significant sex- or
age-based differences in the pharmacokinetic profile
have been reported, even in patients with renal failure.
Therefore, dexmedetomidine does not tend to accumu-
late, in contrast to other agents, such as benzodiazepines
and opioids, which may have an unpredictable and pro-
longed duration of action, especially in critically ill pa-
tients [13].
Post-synaptic activation of α2-adrenergic receptors in
the central nervous system inhibits sympathetic activity
and thus can cause bradycardia and hypotension. Usu-
ally, these temporary effects are successfully treated with
atropine or ephedrine and volume infusions. Often, they
occur during or briefly after the loading dose; thus, they
can be reduced by omitting or reducing it. Additionally,
hypertension may occur during the loading dose or with
high infusion rates [14].
Several studies showed that dexmedetomidine might
enhance patient safety and comfort in long-term sed-
ation. It reduced the incidence of coma and delirium
compared with lorazepam [15]; it reduced duration of
mechanical ventilation and delirium; and, compared with
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communicate about their pain [15].
Conclusions
Dexmedetomidine is a fairly safe and effective antidote
for pediatric marijuana or natural cannabinoid expo-
sures. Its properties and potential to allow for “coopera-
tive” sedation make it a more attractive choice with
fewer side effects than benzodiazepines or opioids.
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journal.
Abbreviations
bpm: Beats per minute; Dex: Dexmedetomidine; GABA: γ-Aminobutyric acid;
ICU: Intensive care unit; OPS: Objective Pain Scale; PICU: Pediatric intensive




The authors declare that they have no competing interests.
Authors’ contributions
FC was a major contributor to the writing of the manuscript. AM, SP, MP and
GC reviewed and corrected the manuscript before submission. All authors
participated in the clinical management of the patient, and all authors read
and approved the final manuscript.
Acknowledgements
The authors thank the PICU nurses who collected vital sign and OPS data.
Received: 2 February 2015 Accepted: 15 June 2015
References
1. Appelboam A, Oades PJ. Coma due to cannabis toxicity in an infant. Eur J
Emerg Med. 2006;13:177–9.
2. Carstairs SD, Fujinaka MK, Keeneo GE, Ly BT. Prolonged coma in a child due
to hashish ingestion with quantitation of the metabolites in urine. J Emerg
Med. 2011;41(3):e69–71.
3. Marcou A, Paon JC, Dufour D, Belgaïd A, Goullé JP, Le Roux P. [Cannabis-
induced toxicity in an 11-month-old child]. Presse Med. 2004;33:940. French.
4. Croche Santander B, Alonso Salas MT, Loscertales Abril M. [Accidental
cannabis poisoning in children: report of four cases in a tertiary care center
from southern Spain]. Arch Argent Pediatr. 2011;109:4–7. Spanish.
5. American Academy of Pediatrics Committee on Drugs. Effects of marihuana
on man. Pediatrics. 1975;56:134–43.
6. Mowry JB, Spyker DA, Cantilena Jr LR, McMillan N, Ford M. 2013 Annual
Report of the American Association of Poison Control Centers’ National
Poison Data System (NPDS): 31st annual report. Clin Toxicol (Phila).
2014;52(10):1032–283.
7. Wang GS, Roosevelt G, Heard K. Pediatric marijuana exposures in a medical
marijuana state. JAMA Pediatr. 2013;167(7):630–3.
8. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals
and humans. Addiction. 1996;91(11):1585–614.
9. Gertler R, Brown HC, Mitchell DH, Silvius EN. Dexmedetomidine: a novel
sedative-analgesic agent. Proc (Bayl Univ Med Cent). 2001;14(1):13–21.
10. Afonso J, Reis F. Dexmedetomidine: current role in anesthesia and intensive
care. Rev Bras Anestesiol. 2012;62:118–33.
11. Panzer O, Moitra V, Sladen RN. Pharmacology of sedative-analgesic agents:
dexmedetomidine, remifentanil, ketamine, volatile anesthetics, and the role
of peripheral mu antagonists. Crit Care Clin. 2009;25:451–69.12. Nelson LE, Lu J, Guo T, Saper CB, Franks NP, Maze M. The α2-adrenoceptor
agonist dexmedetomidine converges on an endogenous sleep-promoting
pathway to exert its sedative effects. Anesthesiology. 2003;98(2):428–36.
13. Gravel NR, Searle NR, Sahab PG, Carrier M. Sedation in critically ill patients:
practical recommendation. CNS Drugs. 1999;11:9–22.
14. Su F, Hammer GB. Dexmedetomidine: pediatric pharmacology, clinical uses
and safety. Expert Opin Drug Saf. 2011;10:55–66.
15. Jakob SM, Ruokonen E, Grounds RM, Sarapohja T, Garratt C, Pocock SJ, et al.
Dexmedetomidine for Long-Term Sedation Investigators. Dexmedetomidine
vs midazolam or propofol for sedation during prolonged mechanical
ventilation: two randomized controlled trials. JAMA. 2012;307(11):1151–60.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
